Figure 8 — RPL22L1 is a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma, promoting the growth and metastasis of LUAD cells by inhibiting the MDM2/P53 signaling pathway | Aging

Navigate

Submit an Article

Research Paper|Volume 16, Issue 17|pp. 12392–12413

RPL22L1 is a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma, promoting the growth and metastasis of LUAD cells by inhibiting the MDM2/P53 signaling pathway

Back to articleFigure 8(8 of 11)

100%

Figure 8.High expression of RPL22L1 in GSE87340 suggests a poor prognosis. (A) The expression of RPL22L1 in GSE87340. (B) OS.